Results 31 to 40 of about 7,752 (219)

Advances in Acute Migraine Therapy: Triptans Compared with CGRP Receptor Antagonists

Journal of Education, Health and Sport
Introduction and purpose: Migraine is one of the most common and disabling neurological disorders. Attacks significantly decrease quality of life and daily functioning; therefore, effective treatment is crucial.
Michał Chodor, Zuzanna Krys, Zuzanna Michalik   +2 more
doaj   +1 more source

Novel pharmaceutical dosage forms of analgesics [PDF]

Arhiv za farmaciju, 2018
Among novel pharmaceutical dosage forms of analgesics, whose number and diversity are continuously increasing over the past two decades, of particular importance are transdermal opioid analgesics (fentanyl, buprenorphine) for the treatment of chronic ...
Đekić Ljiljana, Primorac Marija
doaj   +1 more source

Utilization of triptans in Sweden; analyses of over the counter and prescription sales

, 2014
PURPOSE: To enable easier access to triptans, the drug of choice for moderate to severe migraine, some countries have made triptans available without prescription, that is, over the counter (OTC). Concern has been raised about this. The aim of this study
von Euler, Mia,, Baatz, Katarina,, Keshani, Sara,, Wettermark, Björn,, Keshani, S, Baatz, K, Wettermark, B,, von, Euler M,   +7 more
core   +1 more source

Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system.

PLoS ONE
Tinnitus, a distressing condition that can significantly impair quality of life, has been associated with several medications, including triptans. This study aimed to explore the relationship between tinnitus and specific migraine treatments, focusing on
Yun Kim, Yeabin Yook, Su-Jin Rhee
doaj   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source

Overview of Triptans in the Treatment of Acute Migraine

, 2017
The advent of triptans for effective relief of migraine represented a therapeutic breakthrough. Triptans are serotonin (5-hydroxytryptamine, or 5-HT) agonists with high affinity for 5-HT1B and 5-HT1D receptors.
Chiara Benedetto, Gianni Allais, null null, Pietro Cortelli   +3 more
core   +1 more source

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab

Pharmaceuticals, 2021
Migraine is the second cause of disability and of lost years of healthy life worldwide. Migraine is characterized by recurrent headache attacks and accompanying disabling symptoms lasting 4–48 h.
Damiana Scuteri, Giacinto Bagetta
doaj   +1 more source

Orofacial pain disorder or trigeminal autonomic cephalalgia? Insights into pathophysiology and implications in medicine and dentistry

Headache: The Journal of Head and Face Pain, EarlyView.
There are some headache disorders known as trigeminal autonomic cephalalgias (TACs). When these “headaches” are localized in the mid‐face region, they are known as “trigeminal autonomic orofacial pains” (TAOPs), and they can mimic other types of face pains including dental pain, which puts the patient at risk of receiving treatments that are incorrect.
Marcela Romero‐Reyes, Simon Akerman
wiley   +1 more source

Treatment of Perimenstrual Migraine with Triptans. an Update

, 2012
Pure menstrual migraine (PMM) and menstrually related migraine (MRM) are difficult challenges in migraine management. Triptans are a class of highly selective serotonin receptor agonists, which interfere with the pathogenesis of migraine and are ...
Luana Lionetto, MARTELLETTI, Paolo, CASOLLA, BARBARA, CANDELA, SERENA, NEGRO, ANDREA, SIMMACO, Maurizio, Lidia D'Alonzo   +6 more
core   +1 more source

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

, 2023
International audienceMigraine constitutes the world's second-leading cause of disability. Triptans, as serotonin 5-HT1B/1D receptor agonists, remain the first-line treatment, despite discouraged use in individuals at high cardiovascular risk. Lasmiditan,
Alexandre O. Gérard, Merino, Diane, van Obberghen, Elise, Gérard, Alexandre, Alexandre Destere, Milou-Daniel Drici, Destere, Alexandre, Michel Lanteri-Minet, Diane Merino, Elise K. Van Obberghen, Lanteri-Minet, Michel, Drici, Milou-Daniel   +11 more
core   +1 more source